| [1] |
Makino H, Nishio S, Tsubamoto H, et al. Treatment and prognosis of bone metastasis from cervical cancer (KCOG-G1202s)[J]. J Obstet Gynaecol Res, 2016, 2(6): 701-706. DOI: 10.1111/jog.12956.
|
| [2] |
Ferrandina G, Salutari V, Testa A, et al. Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature[J]. BMC Cancer, 2006, 6: 169.DOI: 10.1186/1471-2407-6-169.
pmid: 16800899
|
| [3] |
Williams JB, Youngberg RA, Bui-Mansfield LT, et al. MR imaging of skeletal muscle metastases[J]. AJR Am J Roentgenol, 1997, 168(2): 555-557.DOI: 10.2214/ajr.168.2.9016246.
|
| [4] |
Agarwal U, Dahiya P, Chauhan A, et al. Scalp metastasis in carcinoma of the uterine cervix—a rare entity[J]. Gynecol Oncol, 2002, 87(3): 310-312. DOI: 10.1006/gyno.2002.6829.
pmid: 12468331
|
| [5] |
Takagi H, Miura S, Matsunami K, et al. Cervical cancer metastasis to the scalp: case report and literature review[J]. Eur J Gynaecol Oncol, 2010, 31 (2): 217-218.
pmid: 20527246
|
| [6] |
Uhrinak AN, Tierney KE, Duncun KL, et al. Intraocular metastasis from primary cervical cancer: a case report and review of the literature[J]. Gynecol Oncol Rep, 2015, 12: 61-63. DOI: 10.1016/j.gore.2015.03.003.
|
| [7] |
王成双, 宋梅, 邹鹏程, 等. 宫颈癌鼻转移1例报告并文献复习[J]. 安徽医药, 2021, 25(10): 2085-2087. DOI: 10.3969/j.issn.1009-6469.2021.10.041.
|
| [8] |
彭海艳, 邱惠, 梅自洁, 等. 宫颈癌胸膜转移一例[J]. 国际肿瘤学杂志, 2020, 47(7): 446-448. DOI: 10.3760/cma.j.cn371439-20200304-00055.
|
| [9] |
周文彪, 徐洁, 蒋小芹, 等. 子宫颈癌胃转移一例报告并文献复习[J]. 中华肿瘤防治杂志, 2019, 26(23): 1814-1817. DOI: 10.16073/j.cnki.cjcpt.2019.23.13.
|
| [10] |
冯铭彬, 刘秦, 陈可盈, 等. 宫颈癌胆囊转移1例报道[J]. 岭南现代临床外科, 2023, 23(5): 424-426. DOI: 10.3969/j.issn.1009-976X.2023.05.010.
|
| [11] |
李帅, 王娟, 夏仕雪, 等. 子宫颈混合性腺神经内分泌癌胰腺转移1例[J]. 中国医学影像学杂志, 2022, 30(12): 1283-1284. DOI: 10.3969/j.issn.1005-5185.2022.12.016.
|
| [12] |
刘美君, 肖雪, 姚远. 疑难宫颈鳞状细胞癌卵巢转移一例[J]. 国际肿瘤学杂志, 2020, 47(2): 127-128. DOI: 10.3760/cma.j.issn.1673-422X.2020.02.014.
|
| [13] |
朱莉, 敖锋. 罕见宫颈癌转移至腰大肌1例[J]. 湖北医药学院学报, 2020, 39(6): 614-615, 651. DOI: 10.13819/j.issn.2096-708X.2020.06.020.
|
| [14] |
Ciccone MA, Conturie CL, Lee CM, et al. Toe metastasis: a rare pattern of cervical cancer spread[J]. Gynecol Oncol Case Rep, 2014, 8: 7-9. DOI: 10.1016/j.gynor.2013.12.004.
|
| [15] |
罗家伦, 徐慧琴, 汪会, 等. 肌肉转移癌的18F-FDG PET/CT影像表现及临床特征研究[J]. 安徽医科大学学报, 2019, 54(5): 753-758. DOI: 10.19405/j.cnki.issn1000-1492.2019.05.019.
|
| [16] |
沈晓燕, 崔恒. 复发性和转移性子宫颈癌化疗的研究进展[J]. 中华妇产科杂志, 2013, 48(10): 788-791. DOI: 10.3760/cma.j.issn.0529-567x.2013.10.016.
|
| [17] |
中国临床肿瘤学会指南工作委员会. 肿瘤临床肿瘤学会(CSCO)宫颈癌诊疗指南2023[M]. 北京: 人民卫生出版社, 2023.
|
| [18] |
Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer[J]. N Engl J Med, 2021, 385(20): 1856-1867. DOI: 10.1056/NEJMoa2112435.
|
| [19] |
周晖, 刘昀昀, 罗铭, 等. 《2022 NCCN子宫颈癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2021, 37(12): 1220-1226. DOI: 10.19538/j.fk2021120112.
|
| [20] |
Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase Ⅱ KEYNOTE -158 study[J]. J Clin Oncol, 2019, 37(17): 1470-1478. DOI: 10.1200/JCO.18.01265.
|
| [21] |
Wang G, Liu Y, He F. Primary lymphoma involving cranial nerves and cauda equina detected by (18)F-FDG PET/CT and MRI[J]. Nuklearmedizin, 2016, 55(5): N46-N48.
pmid: 27668300
|
| [22] |
Liu F, Zhang Q, Zhou D, et al. Effectiveness of 18F-FDG PET/CT in the diagnosis and staging of osteosarcoma: a meta-analysis of 26 studies[J]. BMC Cancer, 2019, 19(1): 323. DOI: 10.1186/s12885-019-5488-5.
|
| [23] |
江涛, 李隆玉, 潘玫, 等. p16在宫颈癌组织中的表达及其意义[J]. 实用癌症杂志, 2005, 20(6): 581-583, 587. DOI: 10.3969/j.issn.1001-5930.2005.06.007.
|
| [24] |
Lin Z, Nan Y, Zhang X, et al. Reverse transcription-polymerase chain reaction and western blotting analysis for detection of p63 isoforms in uterine cervical cancers[J]. Int J Gynecol Cancer, 2006, 16(4): 1643-1647. DOI: 10.1111/j.1525-1438.2006.00638.x.
pmid: 16884378
|
| [25] |
Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)[J]. Lancet, 2017, 390(10103): 1654-1663. DOI: 10.1016/S0140-6736(17)31607-0.
pmid: 28756902
|
| [26] |
Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204 /GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study[J]. Lancet Oncol, 2021, 22(10): 609-619. DOI: 10.1016/S1470-2045(21)00056-5.
|
| [27] |
国家药品监督管理局. 国家药监局附条件批准卡度尼利单抗注射液上市[EB/OL]. (2022-06-29)[2024-04-20]. https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20220629135936153.html.
|
